<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379649</url>
  </required_header>
  <id_info>
    <org_study_id>43265</org_study_id>
    <nct_id>NCT03379649</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma for Patients With Recurrent Implantation Failure</brief_title>
  <official_title>Platelet Rich Plasma for Patients With Recurrent Implantation Failure: A Prospective Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent implantation failure are among the most difficult patients to treat,
      with no proven standard treatment. Platelet rich plasma stimulates cellular processes
      involved in endometrial regeneration, and in a small case series has shown efficacy for this
      patient population. We hope to conduct a randomized controlled pilot study to determine
      whether PRP is indeed an effective treatment for recurrent implantation failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients considered to have recurrent implantation failure will undergo randomization to
      receive intrauterine infusions of platelet rich plasma or a placebo of embryo culture media
      prior to their embryo transfer. All patients will undergo a blood draw to obtain 60ml of
      blood from which 0.5ml of platelet rich plasma will be obtained. Those randomized to receive
      the platelet rich plasma will have platelet rich plasma placed into the uterine cavity at
      least 48 hours prior to the embryo transfer, while those randomized to receive placebo will
      have embryo culture media placed into the uterine cavity at the same point in time. Transfer
      outcomes including implantation rate, pregnancy rate, and live birth rate, will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Patients will be blinded to the treatment they received, but providers and investigators will be aware.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>10 months following transfer</time_frame>
    <description>Live birth/embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>9 days following transfer</time_frame>
    <description>Positive pregnancy test/embryo transferred</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives intrauterine infusion of platelet rich plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives intrauterine infusion of embryo culture media</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Platelet rich plasma</intervention_name>
    <description>Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.</description>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women who have undergone 3 or more embryo (blastocyst stage) transfers without
             establishing a clinical pregnancy or 2 or more euploid embryo transfers without
             establishing a clinical pregnancy, aged 18 - 45, with a normal uterine cavity
             established within 12 months by hysteroscopy or saline infusion sonogram, planning in
             vitro fertilization with an embryo transfer at Stanford Fertility and Reproductive
             Health. The planned transfer must consist of any of the following: a PGS proven
             euploid embryo, a good quality blastocyst from a patient younger than 37, or a donor
             oocyte blastocyst.

        Exclusion Criteria:

          -  Abnormal uterine cavity, planning in vitro fertilization with use of a gestational
             carrier. patients enrolled in other experimental interventions for RIF will be
             excluded. Patients with only poor quality or cleavage stage embryos.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lusine Aghajanova, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Kort, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan D Kort, M.D.</last_name>
    <phone>650-498-7911</phone>
    <email>jkort@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lusine Aghajanova, M.D.</last_name>
    <phone>650-498-7911</phone>
    <email>aghajano@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Fertility and Reproductive Health</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan D Kort, M.D.</last_name>
      <phone>650-498-7911</phone>
      <email>jkort@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nazari L, Salehpour S, Hoseini S, Zadehmodarres S, Ajori L. Effects of autologous platelet-rich plasma on implantation and pregnancy in repeated implantation failure: A pilot study. Int J Reprod Biomed (Yazd). 2016 Oct;14(10):625-628.</citation>
    <PMID>27921085</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jonathan Kort</investigator_full_name>
    <investigator_title>Protocol director</investigator_title>
  </responsible_party>
  <keyword>Recurrent implantation failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

